Omeros (OMER) Receiving Somewhat Positive News Coverage, Analysis Shows

Headlines about Omeros (NASDAQ:OMER) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Omeros earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0275763916892 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ:OMER traded up $0.30 during mid-day trading on Friday, hitting $13.81. The company’s stock had a trading volume of 405,389 shares, compared to its average volume of 1,348,282. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $27.09. The company has a quick ratio of 4.10, a current ratio of 4.12 and a debt-to-equity ratio of -29.93. The firm has a market capitalization of $651.38, a PE ratio of -17.72 and a beta of 3.62.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.03). The company had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $21.94 million. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.45) earnings per share. research analysts expect that Omeros will post -1.51 EPS for the current year.

Several research firms recently weighed in on OMER. ValuEngine upgraded shares of Omeros from a “strong sell” rating to a “sell” rating in a research note on Wednesday. HC Wainwright set a $34.00 target price on shares of Omeros and gave the company a “buy” rating in a research note on Wednesday. WBB Securities reissued a “buy” rating and issued a $75.00 price target on shares of Omeros in a research report on Monday, March 26th. Wedbush lowered shares of Omeros from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $47.00 to $19.00 in a research report on Friday, March 23rd. Finally, BidaskClub raised shares of Omeros from a “strong sell” rating to a “sell” rating in a research report on Friday, March 23rd. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. Omeros has a consensus rating of “Hold” and an average target price of $25.88.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/06/omeros-omer-receiving-somewhat-positive-news-coverage-analysis-shows.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Insider Buying and Selling by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply